If a small drop of blood appears, press with a clean cotton ball
One of the challenges, as you know, Bret, is that in order for research to flourish or to be adequately interrogated, it has to be supported financially
None had a placebo control group
In a single piece, he concisely captures: the state of the field the most important clinical trials where the pipeline is headed These Clinical trials are raising the bar and expanding future treatment options: Retatrutide ~24% weight loss (triple agonist) MariTide 1216% weight loss (GLP-1 + GIP antagonist) CagriSema up to 20% weight loss + ~2% HbA1c drop Orforglipron oral GLP-1, HbA1c 1.5%, weight 7.6% IcoSema weekly semaglutide + once-weekly insulin Even more exciting
Recently, several retrospective studies of patients with T2D and CKD found that although use of GLP1-RA was associated with improved overall survival compared to use of DPP4i, there was no significant difference in cardiovascular outcomes 42,43
HL, hyperlipidemic